Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by decades of advances in discovery, engineering, and manufacturing. Many antibody programs progress efficiently from lead selection into development. At the same time, experience across industry and academia has shown that certain biophysical and manufacturability challenges, such as instability, aggregation, charge heterogeneity, or nonspecific interactions, can become more visible as programs move into formulation, process development, or scale up.
Developability assessment has emerged to better understand these risks earlier in the discovery to development continuum. Rather than predicting clinical success, early developability screening is increasingly used to help teams prioritize candidates with more favorable stability, manufacturability, and formulation profiles, and to flag potential liabilities that may benefit from engineering or optimization.
From binding performance to downstream feasibility
Historically, antibody lead selection has emphasized biological activity, including target binding, potency, and in vivo efficacy. While these properties remain central, downstream challenges are often linked to intrinsic molecular features that are not captured by affinity or functional assays alone. Prior studies have documented that characteristics such as aggregation propensity, hydrophobic surface patches, charge variants, post translational modifications, and self-interaction behavior can influence expression yield, stability, pharmacokinetics, and formulation feasibility.1
As a result, many organizations now incorporate early biophysical profiling as a complementary filter alongside functional screening. These evaluations do not eliminate uncertainty, but they can support more informed tradeoffs when narrowing candidate pools, particularly when multiple leads show comparable biological activity.
Linking discovery decisions with formulation and CMC considerations
One area where early developability data can be particularly informative is formulation strategy. Platform formulations, common in monoclonal antibody development, can accelerate timelines, but they may not be optimal for every molecule.2 Without early insight into a candidate’s colloidal and conformational stability, formulation risks may only become apparent later, when changes are more disruptive and resource intensive.
Formulation and developability assessments help bridge discovery and early CMC by characterizing parameters such as protein-protein interactions, thermal stability, hydrophobicity, aggregation behavior, and charge heterogeneity. These properties can influence decisions about whether a molecule is likely to perform well within a platform approach, or whether more tailored formulation work may be warranted.
What modern developability workflows typically measure
Industry supported frameworks describe developability as a structured evaluation of biochemical, biophysical, and manufacturability attributes, often combining in silico analysis with experimental screening. Common assay panels include measurements of stability, aggregation, self-interaction, hydrophobicity, charge heterogeneity, and nonspecific binding.
In parallel, limited stress and forced degradation studies, such as exposure to temperature, pH shifts, oxidation, and light, can help identify degradation pathways that may later affect manufacturability or product consistency. Case studies from process development groups illustrate how early identification of stability or potency impacting liabilities can inform candidate optimization, process control strategies, or, in some cases, program reprioritization.3
Developability as a decision support tool, not a gatekeeper
Importantly, developability screening is not intended to disqualify candidates solely on the basis of isolated assay readouts. Many molecules with manageable liabilities can progress successfully with appropriate engineering, formulation adjustments, or process controls. Instead, early developability data are increasingly treated as a decision support layer that provides additional context when balancing potency, safety, manufacturability, and commercial considerations.
This probabilistic framing reflects a broader shift toward data informed selection rather than binary pass fail criteria. By identifying potential risks earlier, teams may gain greater flexibility in deciding where to invest optimization effort, how to design mitigation strategies, or when to advance multiple candidates in parallel.
High throughput approaches for larger candidate pools
As antibody discovery pipelines expand, driven in part by automation and AI enabled sequence generation, there is growing demand for developability platforms that can operate at scale. High throughput expression and parallelized assay workflows now make it feasible to evaluate hundreds to thousands of candidates in compressed timelines, supporting earlier and broader triaging without requiring large material commitments.
Integrated, Scalable Developability Assessment from Biointron
To address the increasing scale of modern antibody discovery, Biointron offers an integrated antibody developability assessment platform specifically designed for high-throughput candidate triaging and early-stage optimization.
The platform combines:
- Rapid transient expression workflows
- Multi-parameter biophysical screening (e.g., aggregation tendency, stability, self-interaction, viscosity-related indicators)
- Flexible assay panel customization
- Batch-level capacity to evaluate thousands of monoclonal antibodies
With reported turnaround times of approximately three to five days for customized assay panels, Biointron’s platform is built to support programs generating large immunization-derived repertoires or AI-designed antibody pools. By aligning experimental throughput with modern discovery scale, the platform enables earlier risk visibility, data-driven prioritization, and more efficient downstream development planning.
Looking ahead
Monoclonal antibodies continue to demonstrate strong clinical and commercial performance across therapeutic areas. At the same time, development teams increasingly recognize that understanding molecular behavior beyond binding and potency can improve confidence in downstream decisions. Early developability assessment does not remove uncertainty, but it can reduce blind spots, clarify tradeoffs, and support more strategic candidate selection in an increasingly competitive discovery landscape.
Would you like to find out more about antibody developability?
Visit Biointron’s Learning Center or contact our expert team at [email protected] or +1 (732) 515-4766.
References:
- Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., … Liu, H. (2019). Structure, heterogeneity and developability assessment of therapeutic antibodies. mAbs, 11(2), 239–264. https://doi.org/10.1080/19420862.2018.1553476
- Menzen, T., Le Vay, K., Arsiccio, A., Helbig, C., Hausmann, K., Pabstmann, T., & Hawe, A. (2026). To platform or not to platform: Strategic considerations for antibody formulation in early clinical development. Journal of Pharmaceutical Sciences, 115(1), 104054. https://doi.org/10.1016/j.xphs.2025.104054
- Yang, X., Xu, W., Dukleska, S., Benchaar, S., Mengisen, S., Antochshuk, V., … Ambrogelly, A. (2013). Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. mAbs, 5(5), 787–794. https://doi.org/10.4161/mabs.25269